Compare Hormel Foods Corp (HRL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Sanofi SA — how do they compare? Hormel Foods Corp trades at $19.24 (market cap $10.69B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 8.9× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Sanofi SA for 94 Days on average.
| HRL | SNY | |
|---|---|---|
Market Cap | $10.69B | $95.18B |
Volume | 10,041,387 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $52.34 |
52-Week Low | $19.42 | $39.51 |
Typical Hold Time | 99 Days | 94 Days |
Enterprise Value | $12.67B | $114.48B |
Dividend Yield | 6.02% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.19, down 1.84% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 31.32 above industry norms but attractive P/S of 0.88, while profitability metrics remain modest with 2.82% net margin. Recent $1.06B Brakebush acquisition aims to expand foodservice chicken presence, though dividend sustainability concerns emerge as payout ratios rise amid shrinking profit margins.
Outlook remains cautious with analyst consensus at $24.25 offering 26% upside potential, though only 20% recommend Buy. Key risks include margin compression, acquisition integration challenges, and declining organic growth. The 60-year dividend streak provides support, but investors should monitor whether earnings can sustainably cover growing payouts amid inflationary pressures.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
